EndoQuest will commence its PARADIGM clinical trial for endoluminal robotic colorectal surgery at five leading US hospitals ...

FemPulse announced today that it received FDA investigational device exemption (IDE) approval for its overactive bladder (OAB ...

FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial in female patients suffering ...

EndoQuest Robotics announced today that it received FDA investigational device exemption (IDE) for a study of its surgical ...

RapidPulse, Inc. announced FDA approval of an investigational device exemption (IDE) for the company to study the RapidPulse c ...

In a multicenter, prospective, nonrandomized study evaluating outcomes of fenestrated-branched endovascular aortic repair (FB ...

NeuroPace (NPCE) announced completion of enrollment and implant procedures in its feasibility investigational device exemption, or IDE, study ...

From a company layoff to FDA nods, here are five key developments from spine and orthopedic medtech companies since Dec. 4.

This Investigational Device Exemption study is designed to confirm the safety and effectiveness of Cortiva® Allograft Dermis (ADM) in implant-based breast reconstruction. Cortiva® ADM, commonly used ...

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

has submitted an Investigational Device Exemption (IDE) application for its pivotal colorectal clinical study. EndoQuest's mission is to transform surgical outcomes for minimally invasive surgery (MIS ...

has submitted an Investigational Device Exemption (IDE) application for its pivotal colorectal clinical study. EndoQuest’s mission is to transform surgical outcomes for minimally invasive ...